Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

Carboplatin and Gemcitabine Combination in Metastatic Triple-Negative Anthracycline- and Taxane-Pretreated Breast Cancer Patients: A Phase II Study

(2014) R. Maisano et al.   JOURNAL OF CHEMOTHERAPY

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

(2013) F Zagouri et al.   BRITISH JOURNAL OF CANCER

Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer

(2013) Mevlude Inanc et al.   MEDICAL ONCOLOGY

Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer†

(2012) Y. Fan et al.   ANNALS OF ONCOLOGY

Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network

(2012) Nancy U. Lin et al.   CANCER

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells

(2012) Mayu Yunokawa et al.   CANCER SCIENCE

Frequency of Triple-Negative Breast Cancer in BRCA1 Mutation Carriers: Comparison Between Common Ashkenazi Jewish and Other Mutations

(2012) Nadine Tung et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

CpG island hypermethylation ofBRCA1and loss of pRb as co-occurring events in basal/triple-negative breast cancer

(2011) Olafur Andri Stefansson et al.   Epigenetics

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

(2011) Phuong K. Morrow et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience

(2010) L. Staudacher et al.   ANNALS OF ONCOLOGY

Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells

(2009) T. W. Miller et al.   CLINICAL CANCER RESEARCH

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY